Date
|
Name
|
Institution
|
Seminar
|
| Dec. 9, 2003 |
Robert Doms |
University of Pennsylvania |
Emerging and already emerged: West Nile virus and HIV infection of cells |
| Dec. 2, 2003 |
Susan Zolla-Pazner |
New York University |
Re-examining the V3 Loop and its Role in Inducing Protective Antibodies |
| Nov. 25, 2003 |
Stefan Kaufmann |
Max Planck Institute |
Natural Immune Response to Tuberculosis: Lessons for Rational Vaccine Design |
| Nov. 18, 2003 |
Jon Yewdell |
NIAID, NIH |
In Vivo Veritas: Routes of Viral Antigen Presentation to CD8+ T Cells |
| Nov. 4, 2003 |
Philippa Marrack |
National Jewish Med. Res. Ctr |
T Cell Ligands and the Cells Presenting Them |
| Oct. 28, 2003 |
Steve Rosenberg |
NCI, NIH |
The Development of T-cell Based Immunotherapies for the Treatment of Patients with Cancer |
| Oct. 21, 2003 |
Robert Siliciano |
Johns Hopkins University |
Viral Reservoirs and the Logic of Antiretroviral Therapy for HIV Infection |
| Oct. 7, 2003 |
Richard Wyatt |
Vaccine Research Center, NIH |
Structural and Immunogenic Analysis of HIV Envelope Glycoproteins |
| June 10, 2003 |
Dr. Joern Schmitz |
Harvard University |
The roles of cellular and humoral immunity in controlling SIV replication in vivo |
| June 3, 2003 |
Lewis Lanier |
University of California, San Francisco |
NK cell immunity against viral infection |
| May 27, 2003 |
Klaus Uberla |
Ruhr University |
Lentiviral vectors based on simian immunodeficiency viruses for gene transfer and vaccination |
| May 20, 2003 |
Joern Schmitz |
Harvard University |
The roles of cellular and humoral immunity in controlling SIV replication in vivo |
| May 13, 2003 |
John Shiver |
Merck |
Comparison of viral vector approaches for HIV-1 vaccine development |
| May 6, 2003 |
Julie McElrath |
Fred Hutchinson Cancer Center |
Induction of T cell immunity by HIV-1 immunization and infection |
| Apr. 29, 2003 |
Mike McCune |
Gladstone Institute |
HIV-induced disruption of the CD8+ T cell compartment |
| Apr. 22, 2003 |
Wes Sundquist |
University of Utah |
Cellular Factors and HIV Budding |
| Apr. 15, 2003 |
Raymond Welsh |
University of Massachusetts |
T cell cross-reactivity and heterologous immunity |
| Apr. 9, 2003 |
Tom Wickham |
GenVec, Inc. |
Modifying the receptor specificity of adenovirus vectors to improve their efficiency and specificity for vaccine and other applications |
| Mar. 25, 2003 |
Robin Weiss |
University College London |
Blood group antigens and retrovirus transmission |
| Mar. 11, 2003 |
Genoveffa Franchini |
National Cancer Institute, NIH |
Skewing of dominant responses in macaques immunized with multigenic vaccines |
| Mar. 4, 2003 |
Leo Lefrancois |
University of Connecticut Health Center |
Migration and function of non-lymphoid effector and memory T cells |
| Feb. 25, 2003 |
Jean Stephenne |
GlaxoSmithKline Biologics |
Later Stages of Vaccine Development at GlaxoSmithKline Biologics |
| Feb. 4, 2003 |
Michael Lederman |
Case Western Reserve |
Qualitative and quantitative immune deficits in HIV infection. Does where you were determine where you are? |
| Jan. 28, 2003 |
Warner Greene |
Gladstone Institute |
New insights into the pathogenic interplay of HIV with its cellular host |
| Jan. 21, 2003 |
Mario Stevenson |
University of Massachusetts |
Functions of primate lentiviral Nef proteins |
| Jan. 14, 2003 |
Robert Seder |
Vaccine Research Center, NIH |
Mechanisms controlling Th1 memory cell differentiation: implications for vaccine development against intracellular infections requiring cellular immune responses |